Alpha 2.0
Login Register
» Articles » PMID: 28299344

Advances in Immunotherapy for Glioblastoma Multiforme

Overview
Journal J Immunol Res
Publisher Wiley
Specialty Allergy & Immunology
Date 2017 Mar 17
PMID 28299344
Citations 46
Authors
Boyuan Huang
Hongbo Zhang
Lijuan Gu
Bainxin Ye
Zhihong Jian
Creed Stary
Xiaoxing Xiong
Affiliations
Soon will be listed here.
Abstract

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy. Accumulating evidence suggests that advances in antigen-specific cancer vaccines and immune checkpoint blockade in other advanced tumors may provide an appealing promise for immunotherapy in glioma. The future of therapy for GBM will likely incorporate a combinatorial, personalized approach, including current conventional treatments, active immunotherapeutics, plus agents targeting immunosuppressive checkpoints.

Citing Articles

Hypoxia Dependent Inhibition of Glioblastoma Cell Proliferation, Invasion, and Metabolism by the Choline-Kinase Inhibitor JAS239.

Kelly C, Wydrzynska M, Phelan M, Osharovich S, Delikatny E, See V Metabolites. 2025; 15(2).

PMID: 39997701 PMC: 11857610. DOI: 10.3390/metabo15020076.

Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials.

Palavani L, Mitre L, Camerotte R, Nogueira B, Canto G, Chen H J Neurooncol. 2024; 170(3):483-493.

PMID: 39230804 DOI: 10.1007/s11060-024-04813-0.

Understanding the role of endothelial cells in brain tumor formation and metastasis: a proposition to be explored for better therapy.

Agnihotri T, Salave S, Shinde T, Srikanth I, Gyanani V, Haley J J Natl Cancer Cent. 2024; 3(3):222-235.

PMID: 39035200 PMC: 11256543. DOI: 10.1016/j.jncc.2023.08.001.

Inhibition of glioblastoma cell proliferation and invasion by the choline-kinase inhibitor JAS239 varies with cell type and hypoxia.

Kelly C, Wydrzynska M, Phelan M, Osharovich S, Delikatny E, See V bioRxiv. 2024; .

PMID: 38293093 PMC: 10827177. DOI: 10.1101/2024.01.17.576078.

Correlation of tumor-associated macrophage infiltration in glioblastoma with magnetic resonance imaging characteristics: a retrospective cross-sectional study.

Zhou Q, Xue C, Man J, Zhang P, Ke X, Zhao J Quant Imaging Med Surg. 2023; 13(9):5958-5973.

PMID: 37711787 PMC: 10498259. DOI: 10.21037/qims-23-126.

References
1.
Jie X, Hua L, Jiang W, Feng F, Feng G, Hua Z . Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys. 2011; 62(1):91-9. DOI: 10.1007/s12013-011-9265-6. View
2.
Francis J, Zhang C, Maire C, Jung J, Manzo V, Adalsteinsson V . EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014; 4(8):956-71. PMC: 4125473. DOI: 10.1158/2159-8290.CD-13-0879. View
3.
Pelloski C, Ballman K, Furth A, Zhang L, Lin E, Sulman E . Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007; 25(16):2288-94. DOI: 10.1200/JCO.2006.08.0705. View
4.
Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View
5.
Butterfield L . Dendritic cells in cancer immunotherapy clinical trials: are we making progress?. Front Immunol. 2014; 4:454. PMC: 3861778. DOI: 10.3389/fimmu.2013.00454. View